RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > India’s CDSCO Reduces API Stability Testing Data Requirement

India’s CDSCO Reduces API Stability Testing Data Requirement

Posted 29 October 2014 | By Louise Zornoza

India’s CDSCO Reduces API Stability Testing Data Requirement

This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.

India’s Central Drugs Standard Control Organization (CDSCO) issued a notice on 22 October 2014 cutting the long term stability testing data requirement for active pharmaceutical ingredient (API) exports to the EU from 12 months to 6 months based on results from three batches. 

The accelerated stability data requirement – 6 months – will remain the same, CDSCO said.

In order to obtain the Written Confirmation Certificate (WC) from the CDSCO that is required by the EU, the API exporter must establish that there were no major changes from the specifications under the lowered testing threshold.  Moreover, the exporter must submit a stability protocol that commits the manufacturer to an ongoing stability program and requires the manufacturer to assign retest/expiry dating according to ICH guidelines.

(CDSCO Notice)

Regulatory Focus newsletters

All the biggest regulatory news and happenings.